journal article·2025Open access

Mechanistic investigation of calcium phosphate mineralization potentiating the cellular immune response of foot-and-mouth disease virus-like particle vaccines

Zhidong Teng, Jiajun Li, Mei Ren, Qianqian Xie, Hu Dong, Jingjing Zhou, Suyu Mu, Manyuan Bai, Shiqi Sun, Huichen Guo

Nanoscale· Volume 17· Issue 25

Abstract

Virus-like particles (VLPs), composed of structural proteins, have emerged as a promising vaccine platform for preventing infectious diseases due to their outstanding advantages. Enhancing immune responses specific to VLPs, particularly cellular immunity, has emerged as a pivotal area of current immunological research. The nanovaccines for the foot-and-mouth disease virus (FMDV) composed of VLPs mineralized with calcium phosphate (VLPs-CaP), developed based on biomineralization principles, demonstrates superior immunogenicity. In this study, we elucidated the efficacy and mechanism of VLPs-CaP in eliciting cellular immune responses. The results demonstrated that VLPs-CaP were efficiently internalized by dendritic cells (DCs) via energy-dependent endocytosis mediated by actin, microtubules, and clathrin. Upon uptake, VLPs-CaP decomposed within lysosomes, leading to the release of Ca2+ ions and an increase in lysosomal permeability. This facilitates the escape of VLPs into the cytoplasm for cross-presentation. Furthermore, CaP mineralization enhanced the level of activation of DCs by FMDV VLPs, evidenced by elevated expression of CD40 and CD86, and the secretion of IL-2 and IL-12p70. Immunization studies in mice revealed that VLPs-CaP elicited higher levels of specific antibodies compared to unmineralized VLPs; notably, there was an increased IgG2a/IgG1 ratio along with a greater number of cytotoxic T lymphocytes (CTLs). This study elucidated the mechanism by which CaP-mineralized VLPs induce cellular immune responses, offering new insights and strategies aimed at enhancing the cellular immune efficacy of VLP-based vaccines that primarily elicit humoral immunity.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Animal Disease Management and Epidemiology · Viral Infections and Immunology Research · Viral Infectious Diseases and Gene Expression in Insects

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China

College of Veterinary Medicine, Gansu Agricultural University, Lanzhou, China

School of Life Sciences, Ningxia University, Yinchuan, China

Funding

National Natural Science Foundation of China · Key Science and Technology Foundation of Gansu Province · Natural Science Foundation of Gansu Province · China Postdoctoral Science Foundation

References (54)

Show source-provided references
1. Frietze · Curr. Opin. Virol. · 2016 · 18 · 4410.1016/j.coviro.2016.03.001 ↗
2. Fuenmayor · New Biotechnol. · 2017 · 39 · 17410.1016/j.nbt.2017.07.010 ↗
3. Mohsen · Semin. Immunol. · 2017 · 34 · 12310.1016/j.smim.2017.08.014 ↗
4. Guo · Vet Res · 2013 · 44 · 4810.1186/1297-9716-44-48 ↗
5. Xiao · Front. Vet. Sci. · 2021 · 8 · 63370610.3389/fvets.2021.633706 ↗
6. Li · ACS Nano · 2022 · 16 · 1048210.1021/acsnano.2c01283 ↗
7. Karakus · Nat. Microbiol. · 2024 · 9 · 262610.1038/s41564-024-01771-1 ↗
8. Amanna · Virology · 2011 · 411 · 20610.1016/j.virol.2010.12.016 ↗
9. Seder · Nature · 2000 · 406 · 79310.1038/35021239 ↗
10. Zhou · ACS Appl. Bio Mater. · 2023 · 6 · 351610.1021/acsabm.3c00109 ↗
11. Zeng · Nat. Mater. · 2025 · 24 · 28710.1038/s41563-024-02093-7 ↗
12. Li · WIREs Nanomed. Nanobiotechnol. · 2021 · 1310.1002/wnan.1706 ↗
13. Wang · Acta Biomater. · 2019 · 86 · 41610.1016/j.actbio.2019.01.002 ↗
14. Guo · Acta Pharm. Sin. B · 2023 · 13 · 507410.1016/j.apsb.2023.08.028 ↗
15. Chiu · Bioconjugate Chem. · 2012 · 23 · 61010.1021/bc200654v ↗
16. Zhou · Nanomedicine · 2014 · 10 · 57110.1016/j.nano.2013.11.007 ↗
17. Su · J. Nanobiotechnol. · 2023 · 21 · 12010.1186/s12951-023-01870-x ↗
18. Zhong · J. Controlled Release · 2019 · 300 · 8110.1016/j.jconrel.2019.02.035 ↗
19. Zeng · Nat. Mater. · 2025 · 24 · 28710.1038/s41563-024-02093-7 ↗
20. Spencer · Front. Mater. · 2021 · 810.3389/fmats.2021.681415 ↗
21. Corripio-Miyar · Vaccines · 2023 · 1110.3390/vaccines11071229 ↗
22. Goto · Vaccine · 1997 · 15 · 136410.1016/S0264-410X(97)00054-6 ↗
23. Hayashi · Vaccine · 2016 · 34 · 30610.1016/j.vaccine.2015.11.059 ↗
24. Jiang · Nucleic Acids Res. · 2025 · 53 · D167010.1093/nar/gkae973 ↗
25. Guo · Vaccines · 2021 · 910.3390/vaccines9080891 ↗
26. Naahidi · J. Controlled Release · 2013 · 166 · 18210.1016/j.jconrel.2012.12.013 ↗
27. Cai · Biomaterials · 2014 · 35 · 228310.1016/j.biomaterials.2013.11.088 ↗
28. Apodaca · Traffic · 2001 · 2 · 14910.1034/j.1600-0854.2001.020301.x ↗
29. Kaksonen · Nat. Rev. Mol. Cell Biol. · 2018 · 19 · 31310.1038/nrm.2017.132 ↗
30. Wang · Nat. Biomed. Eng. · 2025 · 9 · 20110.1038/s41551-025-01343-6 ↗
31. Ma · Signal Transduction Targeted Ther. · 2021 · 6 · 35310.1038/s41392-021-00752-8 ↗
32. Spolski · Nat. Rev. Immunol. · 2018 · 18 · 64810.1038/s41577-018-0046-y ↗
33. Garris · Immunity · 2022 · 55 · 174910.1016/j.immuni.2022.07.021 ↗
34. Gilmour · npj Vaccines · 2024 · 9 · 8310.1038/s41541-024-00869-1 ↗
35. Zobywalski · J. Transl. Med. · 2007 · 5 · 1810.1186/1479-5876-5-18 ↗
36. Pipkin · Immunity · 2010 · 32 · 7910.1016/j.immuni.2009.11.012 ↗
37. Johnson · Proc. Natl. Acad. Sci. U. S. A. · 2003 · 100 · 265710.1073/pnas.0538056100 ↗
38. Rappazzo · Nat. Commun. · 2020 · 11 · 441410.1038/s41467-020-18204-2 ↗
39. Hirschhorn · Cell · 2023 · 186 · 143210.1016/j.cell.2023.03.007 ↗
40. Tan · Eur. J. Immunol. · 1997 · 27 · 242610.1002/eji.1830270942 ↗
41. Colbert · Curr. Opin. Immunol. · 2020 · 64 · 110.1016/j.coi.2019.12.005 ↗
42. Chen · Biomaterials · 2022 · 288 · 12174810.1016/j.biomaterials.2022.121748 ↗
43. Du · Curr. Opin. Biotechnol · 2020 · 66 · 11310.1016/j.copbio.2020.06.015 ↗
44. Liu · Chem. Mater. · 2024 · 36 · 501710.1021/acs.chemmater.3c03338 ↗
45. Toellner · J. Exp. Med. · 1998 · 187 · 119310.1084/jem.187.8.1193 ↗
46. Strid · Immunology · 2006 · 119 · 2710.1111/j.1365-2567.2006.02401.x ↗
47. Luckheeram · Clin. Dev. Immunol. · 2012 · 2012 · 92513510.1155/2012/925135 ↗
48. Suzuki · Surgery · 2010 · 148 · 57310.1016/j.surg.2010.01.017 ↗
49. Choi · Clin. Exp. Immunol. · 1998 · 113 · 31710.1046/j.1365-2249.1998.00690.x ↗
50. Poran · Genome Med. · 2020 · 12 · 7010.1186/s13073-020-00767-w ↗
51. Paucek · Trends Immunol. · 2019 · 40 · 29210.1016/j.it.2019.02.002 ↗
52. Saeed · Clin. Exp. Vaccine Res. · 2015 · 4 · 8810.7774/cevr.2015.4.1.88 ↗
53. MacLeod · Proc. Natl. Acad. Sci. U. S. A. · 2011 · 108 · 791410.1073/pnas.1104588108 ↗
54. Wu · Signal Transduction Targeted Ther. · 2022 · 7 · 1810.1038/s41392-022-00874-7 ↗